Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) stock drops despite market gains: Important facts to note
In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.60, marking a -4% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.26%.
Recursion Pharmaceuticals, Inc. (RXRX) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 12:45 PM EDTCompany ParticipantsBen Taylor - ...
View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.
Investing.com -- Recursion Pharmaceuticals executives discussed the company’s artificial intelligence-driven drug discovery ...
Salt Lake City, April 07, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in ...
One of these is not like the other.
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) stock declines while market improves: Some information for investors
Recursion Pharmaceuticals (RXRX) closed at $3.32 in the latest trading session, marking a -2.06% move from the prior day. This change lagged the S&P 500's daily gain of 0.62%. Meanwhile, the Dow ...
Nvidia’s forthright ambitions to expand its drug development footprint are coming into focus, with the global computing powerhouse announcing a trio of new initiatives including a new collaboration ...
This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...
Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.37, indicating a +1.51% shift from the previous trading day.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results